LODOSYN Drug Patent Profile

When do Lodosyn patents expire, and what generic alternatives are available?

Lodosyn is a drug marketed by Aton and is included in one NDA.

The generic ingredient in LODOSYN is carbidopa. There are eighteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the carbidopa profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lodosyn

A generic version of LODOSYN was approved as carbidopa by ALVOGEN on January 8^th, 2016.

Summary for LODOSYN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	10
Patent Applications:	5,172
Drug Prices:	Drug price information for LODOSYN
What excipients (inactive ingredients) are in LODOSYN?	LODOSYN excipients list
DailyMed Link:	LODOSYN at DailyMed

See drug prices for LODOSYN

Recent Clinical Trials for LODOSYN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Miami	Phase 2
Daniel Claassen	Phase 1
University of Miami	Phase 1

See all LODOSYN clinical trials

US Patents and Regulatory Information for LODOSYN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aton	LODOSYN	carbidopa	TABLET;ORAL	017830-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes

Expired US Patents for LODOSYN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Aton	LODOSYN	carbidopa	TABLET;ORAL	017830-001	Approved Prior to Jan 1, 1982
Aton	LODOSYN	carbidopa	TABLET;ORAL	017830-001	Approved Prior to Jan 1, 1982
Aton	LODOSYN	carbidopa	TABLET;ORAL	017830-001	Approved Prior to Jan 1, 1982

International Patents for LODOSYN

See the table below for patents covering LODOSYN around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	318573
Yugoslavia	185878
Czechoslovakia	178085
Yugoslavia	35107
Germany	2062285

LODOSYN Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for the Drug: LODOSYN

Introduction to LODOSYN

LODOSYN, also known as carbidopa, is a crucial medication in the treatment of Parkinson's disease. It is used in conjunction with levodopa or carbidopa-levodopa to manage the symptoms of Parkinson's, such as stiffness, tremors, and poor muscle control[4].

Market Overview of Parkinson's Disease

The global Parkinson's disease market is projected to experience significant growth. By 2029, the market is estimated to reach $5.2 billion, representing a 43% increase from 2019 and a compound annual growth rate (CAGR) of 4%[3].

Prevalence and Demographics

The prevalence of Parkinson's disease is expected to double over the next 30 years due to aging populations and improved survival rates. This demographic shift will drive the demand for effective treatments, including LODOSYN[3].

Role of LODOSYN in Parkinson's Treatment

LODOSYN plays a vital role in the management of Parkinson's disease by inhibiting the conversion of levodopa to dopamine outside the brain. This action reduces the side effects of nausea and vomiting associated with levodopa therapy and allows for the administration of lower doses of levodopa with a smoother medication response[1][4].

Clinical Indications

LODOSYN is indicated for use with carbidopa-levodopa or with levodopa in the treatment of idiopathic Parkinson’s disease, postencephalitic parkinsonism, and symptomatic parkinsonism. It is particularly useful in patients who require separate titration of carbidopa and levodopa or those who need more than the standard daily dosage of carbidopa provided by carbidopa-levodopa combinations[1][4].

Market Dynamics

Competitive Landscape

The Parkinson's disease market is characterized by a mix of established therapies and new drug delivery systems. While LODOSYN is a well-established drug, the market is expected to see new launches and the loss of patent protection for several leading therapies between 2020 and 2029. This will result in a net gain of approximately $10 billion in revenue, despite some regions like Japan experiencing negative value growth due to more loss of protection events[3].

Regional Variations

The impact of new drug launches and patent expirations varies by region. North America and Australia/New Zealand (AUNZ) are expected to see significant positive value growth due to a higher number of new drug launches. In contrast, Japan will experience more loss of protection events, leading to negative value growth in that region[3].

Financial Trajectory

Revenue Projections

The acquisition of LODOSYN by Aton Pharma marked a significant step in the drug's financial trajectory. Given the growing demand for Parkinson's disease treatments, LODOSYN is expected to contribute substantially to the revenue of its marketing and distribution companies.

Market Value Growth

The global Parkinson's disease market, driven by the increasing prevalence of the disease and the introduction of new therapies, is expected to grow significantly. LODOSYN, as a key component of Parkinson's treatment regimens, will likely benefit from this growth, contributing to the overall market value increase of $5.2 billion by 2029[3].

Impact of Patent Expirations

While LODOSYN itself is not subject to recent patent expirations, the broader market dynamics will influence its financial performance. The loss of patent protection for other leading therapies will create opportunities for generic and innovative treatments, potentially affecting the market share and pricing of LODOSYN[3].

Distribution and Marketing

Acquisition and Distribution Rights

Aton Pharma's acquisition of the U.S. marketing rights to LODOSYN from Bristol-Myers Squibb Company marked a significant milestone. This acquisition enabled Aton Pharma to assume exclusive responsibility for the U.S. sales and distribution of LODOSYN, enhancing its presence in the Parkinson's disease market[1].

Patient Outcomes and Quality of Life

Clinical Benefits

The use of LODOSYN with levodopa or carbidopa-levodopa improves patient outcomes by allowing for lower doses of levodopa, reducing side effects such as nausea and vomiting, and enabling more rapid dosage titration. This results in a smoother medication response and better control of Parkinson's symptoms[1][4].

Expert Insights

"LODOSYN plays a key role in my Parkinson's patients for whom the dosage of levodopa is less than adequate. LODOSYN permits control of Parkinson's symptoms with much lower doses of levodopa and a resulting reduction in side effects," explained Dr. George Plotkin, M.D., Ph.D., of the Movement Disorder Center in Tyler, TX[1].

Conclusion

LODOSYN is a critical medication in the treatment of Parkinson's disease, and its market dynamics are closely tied to the broader trends in the Parkinson's disease market. With the global market projected to grow significantly, LODOSYN is poised to continue playing a vital role in improving patient outcomes and contributing to the financial growth of its marketing and distribution companies.

Key Takeaways

• Growing Market: The global Parkinson's disease market is expected to reach $5.2 billion by 2029.
• Clinical Importance: LODOSYN is essential for managing Parkinson's symptoms by reducing the side effects of levodopa therapy.
• Regional Variations: Market growth will vary by region, with North America and AUNZ seeing positive growth and Japan experiencing negative growth.
• Financial Impact: LODOSYN will contribute to the revenue growth of its marketing companies, despite market dynamics influenced by patent expirations.
• Patient Benefits: LODOSYN improves patient outcomes by allowing lower doses of levodopa and reducing side effects.

FAQs

What is LODOSYN used for?

LODOSYN (carbidopa) is used with levodopa or carbidopa-levodopa to treat the symptoms of Parkinson's disease, including stiffness, tremors, and poor muscle control[4].

How does LODOSYN work?

LODOSYN inhibits the conversion of levodopa to dopamine outside the brain, reducing side effects and allowing for lower doses of levodopa with a smoother medication response[1][4].

What are the benefits of using LODOSYN with levodopa?

Using LODOSYN with levodopa reduces nausea and vomiting, allows for more rapid dosage titration, and provides a smoother medication response[1][4].

Who acquired the U.S. marketing rights to LODOSYN?

Aton Pharma acquired the U.S. marketing rights to LODOSYN from Bristol-Myers Squibb Company in 2010[1].

What is the projected growth of the Parkinson's disease market?

The global Parkinson's disease market is projected to grow to $5.2 billion by 2029, representing a 43% increase from 2019[3].

Sources

1. Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) - PR Newswire
2. AMI ORGANICS LIMITED - BSE Listing Centre - BSE Listing Centre
3. Novel Drug Delivery Systems Drive Value Growth in the Parkinson's ... - IQVIA
4. Lodosyn (Carbidopa): Side Effects, Uses, Dosage, Interactions ... - RxList
5. Gut Microbiota Approach— - Frontiers in Cellular and Infection Microbiology